The Global Health Body Sounds Concern Over Acute Shortage of Weight-Loss Injections
Less than one in 10 patients that would benefit from weight-loss injections like Wegovy can access them, states the World Health Organization as it publishes its initial advice on the therapies.
Given more than one billion individuals worldwide now classified as obese, it is advocating for increased and just availability to GLP-1 medication.
According to forecasts, more than two billion are projected to be obese by 2030 unless action is taken.
"Our latest guidance affirms that obesity is a chronic disease that can be managed with holistic and continuous treatment," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are key barriers to widespread availability to the treatments that can assist patients in reducing considerable weight, says the body.
Skinny Jab Scarcity
Even in the current most favorable outlook, the production of these medications might only reach about 100 million people – less than 10% of those who need them, per the health organization.
The advice calls on countries and companies to widen availability, by approaches including patent sharing.
Exclusive production rights on a key compound – the primary component of Novo Nordisk's Wegovy – is scheduled to end in a number of countries in 2026.
How Weight-Loss Drugs Function
The injections imitate a body's own hormone to delay gastric emptying, suppress the appetite and boost the sense of being full so users eat less.
Patients usually see weight reduction after several weeks of commencing the weekly injections.
Studies suggests people may see weight return a year later of stopping the medication, when their usual hunger come back.
Being overweight or obese increases your risk for contracting medical conditions, like diabetes, cardiovascular issues, stroke, and specific malignancies.
Obesity impacts people in every country and was responsible for 3.7 million deaths worldwide in 2024, according to the WHO.
